Recent advances of multimodal ultrasound in image-guided prostate-targeted biopsy

**ARTICLE INFO**

**Keywords**
- Prostate
- Targeted biopsy
- Ultrasound

**ABSTRACT**

Prostate-targeted biopsy is usually the preferred method over systematic biopsy because it can effectively detect prostate cancer using only a few puncture cores with fewer complications. With the development of ultrasound, it has gained multimodal technological upgrades, such as the emergence of contrast-enhanced ultrasound, ultrasound elastography, and three-dimensional ultrasonography. Moreover, multimodal ultrasound has played an increasingly significant role in prostate-targeted biopsies.

Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide, with approximately 1.4 million new cases diagnosed each year. As the current “gold standard” for confirming the diagnosis of PCa, prostate biopsy, including systematic biopsy and targeted biopsy, has been widely used in clinical practice since it was first introduced by Hodge et al. in the 1980s. Significantly, a targeted biopsy is usually the preferred method over systematic biopsy because it can effectively detect PCa using only a few puncture cores with fewer complications. Therefore, precise characterization of the target lesion and performing the targeted biopsy has long been a hot research issue.

Transrectal ultrasonography (TRUS), a universally available imaging modality, has been applied in prostate disease diagnosis because it is a convenient and non-invasive examination technique. In recent years, multimodal technological upgrades have been developed, such as the emergence of contrast-enhanced ultrasound, ultrasound elastography, and three-dimensional ultrasonography. The diversity of imaging manifestations of PCa facilitates a wide range of applications of multimodal ultrasound techniques in prostate-targeted biopsies. For example, abnormal hypoechoicinity in gray-scale ultrasound, rich blood flow signals in color or power Doppler ultrasound, focal asymmetry hyper-enhancement on contrast-enhanced ultrasound, ultrasound elastography, and three-dimensional ultrasonography. Imaging of mechanical focal hypoechogenicity is usually indicative of PCa. Additionally, color or power Doppler ultrasound can be used to test prostate blood flow signals. If there were any abnormal hypoechoicinity or blood flow signals, an image-guided targeted biopsy was performed (Fig. 1, A-C). Although 2D-TRUS has been routinely applied in prostate disease diagnosis because of its unique advantages of skillful operation and easy control, relatively low sensitivity in PCa localization limits its independent use in targeted biopsies. Moreover, the low resolution of detailed anatomical structures has also resulted in a reduced positive biopsy rate. Many researchers have recommended adding in some more puncture cores based on 2D-TRUS-targeted biopsy to improve the rate of PCa detection. However, some PCa lesions might still be missed even if a “saturation” biopsy approach to obtaining enough cores has been employed. However, it is worth mentioning that 2D-TRUS has an important function in guiding MRI-targeted biopsies in real-time.

2. **MRI-ultrasound fusion/cognitive targeted biopsy (MRI-TBx)**

The value of multiparametric magnetic resonance imaging (mp-MRI) for identifying PCa lesions has been verified. Many international guidelines have already recommended prebiopsy mp-MRI examinations because it has been proved that mp-MRI could improve the detection rate of PCa and reduce unnecessary biopsies by 25%. The exceptional performance of mp-MRI in PCa detection further facilitated MRI-guided targeted biopsy as a possible option. However, some intrinsic shortcomings (e.g., complex operations, specialized settings, low availability, and high cost) have restricted the widespread use of MRI-guided targeted biopsies. Therefore, to supplement the limitations of mp-MRI, 2D-TRUS raises concern as a feasible alternative and is fused with MRI to guide targeted biopsy (Fig. 2). Moreover, considering the complicated and time-consuming process of image fusion, MRI-ultrasound cognitive targeted biopsy is gradually being used. However, its PCa detection rate largely depends on the experience of the operator, which has slight
As MRI-ultrasound fusion/cognitive targeted biopsy (MRI-TBx) has been increasingly recognized in clinical practice, 2D-TRUS has become an essential part of prostate biopsy. Despite the growing acknowledgment of mp-MRI, there are still some limitations, such as moderate specificity and variable negative predictive values of 63%–98%. In addition, mp-MRI might miss or even characterize some PCa lesions as benign, with a ratio of approximately 58%. Furthermore, the biopsy revealed PCa in 5%–15% of men with negative MRI findings. Therefore, it is essential to combine MRI-TBx with multimodal ultrasound to more accurately diagnose PCa.

3. Contrast-enhanced transrectal ultrasonography (CE-TRUS)

Contrast-enhanced transrectal ultrasonography (CE-TRUS) has been widely used in prostate disease diagnosis in recent years because it can dynamically display blood perfusion and vascularity, especially micro-nourishing vessels related to tumors that may not have sufficient native flow to be detected by conventional color or power Doppler ultrasound. Focal asymmetry hyperenhancement during the early phase of prostate cancer by CE-TRUS is usually indicative of PCa and can be characterized as a lesion for targeted biopsy (Fig. 1, D). In addition, owing to the

![Fig. 1. Prostate cancer (PCa) in the right peripheral zone of prostate. A 65-year-old man with PSA 13.06 ng/ml underwent a 2-core targeted biopsy followed by a 12-core systematic biopsy and histopathology detected PCa of Gleason 4 + 4. (A) Gray-scale ultrasound shows that there is an asymmetrical focal hypoechoic lesion in the right peripheral zone (arrow). (B, C) Color and Power Doppler ultrasound reveal rich blood flow signals (arrow). (D) Contrast-enhanced transrectal ultrasonography (CE-TRUS) shows abnormal hyperenhancement earlier than adjacent normal tissues (arrow) during the early phase. (E) Transrectal shear wave elastography (SWE) shows a relatively hard red-coded map of the right peripheral zone (arrow). (F) Transrectal real-time strain elastography (TRSE) also reveals abnormal asymmetry stiffer region (arrow).]
angiogenesis of PCa in the early stage, CE-TRUS may be extremely sensitive to lesion localization. Compared to 2D-TRUS, CE-TRUS is better in early detection of the blood flow in tumors and can improve the accuracy of ultrasound. Therefore, CE-TRUS is widely applicable to prostate-targeted biopsy. It was proven that the positive rate of CE-TRUS-targeted biopsy was higher than that of systematic biopsy, especially for PCa with a higher Gleason score. Some studies have shown that the combination of CE-TRUS-targeted biopsy and systematic biopsy can improve the detection rate. However, some drawbacks of CE-TRUS, including increased cost, inability to scan the whole prostate during one administration of the contrast agent, contrast agent allergy, and time consumption, should attract attention. Moreover, there are some limitations of CE-TRUS in detecting extensive tumors with relatively low Gleason scores.

4. Transrectal shear wave elastography (SWE)

The proportion of extracellular matrix proteins associated with tumors would increase during PCa formation and is involved in the improvement of tissue stiffness in the PCa region. Transrectal shear wave elastography (SWE) can be used to qualitatively and quantitatively analyze prostate tissue stiffness. The PCa region is generally stiffer than the surrounding normal tissue. Thus, abnormally stiffer regions in the prostate were characterized for targeted biopsy (Fig. 1, E). SWE could present a red-coded area suspicious of PCa with greater stiffness, which 2D-TRUS failed to identify. SWE could additionally characterize approximately 60% of the clinically significant PCa missed by MRI. The detection rate of PCa can be improved by 10% after combining SWE with MRI. Compared to systematic biopsy, SWE-targeted biopsy could improve the detection rate of PCa. Moreover, SWE can effectively predict PCa extracapsular extension, although negative manifestations cannot entirely exclude extracapsular extension. However, the instability and dependence of SWE on operators limit its potential for wide clinical use. In addition, SWE is usually used to assess the stiffness of the outer glands, but it is difficult to accurately measure the stiffness of the inner glands.

5. Transrectal real-time strain elastography (TRSE)

Transrectal real-time strain elastography (TRSE) is another technique used to analyze tissue stiffness. Unlike SWE, TRSE must be performed by applying additional pressure on tissues and assessing stiffness based on the degree of tissue deformation. Similarly, abnormal regions, especially asymmetrically stiffer regions detected by TRSE in the prostate, could be characterized by targeted biopsy (Fig. 1, F). Previous research has shown that TRSE-targeted biopsy could improve the detection rate of PCa by 18.3%–24.8%. By combining TRSE-targeted biopsy with systematic biopsy, the negative predictive value for high-risk PCa can be improved from 79% to 97%. Moreover, the study conducted by Kamo et al. proposed the “TRSE 5-point” method, taking 3-point as the cut-off value to differentiate the presence from the absence of PCa; the sensitivity, specificity, and accuracy were 68%, 81%, and 76%, respectively. Similar to SWE, TRSE can also accurately predict the extracapsular extension of PCa. However, TRSE has limitations in detecting small PCa lesions and may miss PCa with a low Gleason score. In addition, TRSE has limitations in identifying suspicious lesions owing to its high dependence on operators.

6. Three-dimensional transrectal ultrasonography (3D-TRUS)

Three-dimensional transrectal ultrasonography (3D-TRUS) has emerged as a novel imaging technique in prostate-targeted biopsy to provide a precise anatomic localization (Fig. 3). The 3D-TRUS helps acquire 3D images and remedies the shortage of 2D-TRUS for measuring the volumes of lesions. Moreover, 3D-TRUS can cover large regions of interest, including peripheral blood vessels. The 3D model of a real-time puncture route was reconstructed to record the position of the puncture needle and to perform a targeted biopsy more visually and accurately. Therefore, 3D-TRUS is often a better choice for repeated biopsies and for identifying lesions, especially small target lesions. Compared with 2D-TRUS, 3D-TRUS with a higher localizing accuracy could improve the efficiency of MRI-ultrasound fusion/cognitive.
targeted biopsy and increase the rate of PCa detection. However, a complex reconstruction operation is still a deficiency of 3D-TRUS, which awaits further improvement.

In conclusion, with the development of multimodal ultrasound, various ultrasound techniques are widely used in prostate-targeted biopsies. Many studies have shown that multimodal ultrasound-targeted biopsy could effectively improve the rate of PCa detection. Although at present, MRI-targeted biopsy guided by 2D-TRUS is the mainstream technique in prostate-targeted biopsy, multimodal ultrasound is a reliable auxiliary technique to supplement the deficiency of MRI. It is essential to understand that multimodal ultrasound is not merely an auxiliary technique and is more likely to become the mainstream in targeted biopsy in near future as a positive prospect in clinical application. Although, the role of multimodal ultrasound in prostate-targeted biopsy still needs further exploration and confirmation.

Declaration of competing interest

No conflict of interest exists in the submission of this manuscript, and all authors have approved the manuscript for publication.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
2. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71–74, discussion 74–75.
3. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100–109.
4. Ahboud M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382:917–926.
5. Tschirsidehawan S, Wiesenfarth M, Bonekamp D, et al. Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography-fusion biopsy. Eur Urol Focus. 2021;7:1300–1307.
6. Díaz AB, O’Brien C, Correas JM, et al. Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review. Br J Radiol. 2022;95, 20210633.
7. Cool DW, Zhang X, Romagnoli C, et al. Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. AJR Am J Roentgenol. 2015;204:83–91.
8. Wetterzauer C, Trotzenko P, Mathias MO, et al. Diagnostic accuracy and clinical implications of robotic assisted MRI-US fusion guided target saturation biopsy of the prostate. Sci Rep. 2021;11, 20250.
9. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–822.
10. Thompson JE, van Leeuwen PJ, Moses D, et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol. 2016;195:1428–1435.
11. Pagniez MA, Kasivisvanathan V, Puech P, et al. Predictive factors of missed clinically significant prostate cancers in men with negative magnetic targeting imaging: a systematic review and meta-analysis. J Urol. 2020;204:24–32.
12. Gorin MA, Meyer AB, Zimmerman M, et al. Transperineal prostate biopsy with cognitive magnetic resonance imaging/biplane ultrasound fusion: description of technique and early results. World J Urol. 2020;38:1943–1949.
13. Mortezavi A, Maizendorfer O, Donati OF, et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. J Urol. 2018;200:309–318.
14. Borofsky S, George AK, Gaur S, et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology. 2018;286:186–195.
15. Kasivisvanathan V, Ransniko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767–1777.
16. Correas JM, Halpern EJ, Barr RG, et al. Advanced ultrasound in the diagnosis of prostate cancer. World J Urol. 2021;39:661–676.
17. Yang G, Ruan L. Imaging findings of prostate tuberculosis by transrectal contrast-enhanced ultrasound and comparison with 2D ultrasound and pathology. Br J Radiol. 2022;95, 20210713.
18. Sano F, Terao H, Kawahara T, et al. Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer. BJU Int. 2011;107:1404–1410.
19. Strandzina A, Krumina G, Sperga M. The value and limitations of contrast-enhanced ultrasound in detection of prostate cancer. Anticancer Res. 2011;31:1421–1426.
20. Mongiat M, Buraschi S, Andreuzzi E, et al. Extracellular matrix: the gatekeeper of tumor angiogenesis. Biochem Soc Trans. 2019;47:1543–1555.

21. Xiang LH, Fang Y, Wan J, et al. Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging. Eur Radiol. 2019;29:6682–6689.

22. Correas JM, Tissier AM, Khairoune A, et al. Prostate cancer: diagnostic performance of real-time shear-wave elastography. Radiology. 2015;275:280–289.

23. Ageeli W, Wei C, Zhang X, et al. Quantitative ultrasound shear wave elastography (USWE)-measured tissue stiffness correlates with PI-RADS scoring of MRI and Gleason score on whole-mount histopathology of prostate cancer: implications for ultrasound image-guided targeting approach. Insights Imaging. 2021;12:96.

24. Zhang Y, Tang J, Li YM, et al. Differentiation of prostate cancer from benign lesions using strain index of transrectal real-time tissue elastography. Eur J Radiol. 2012;81:857–862.

25. Pallwein L, Mitterberger M, Struve P, et al. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol. 2007;17:2278–2285.

26. Kamoi K, Okihara K, Ochiai A, et al. The utility of transrectal real-time elastography in the diagnosis of prostate cancer. Ultrasound Med Biol. 2006;34:1025–1032.

27. Salomon G, Köllerman J, Thederan I, et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol. 2006;54:1354–1362.

28. Salomon G, Schiffmann J. Real-time elastography for the detection of prostate cancer. Curr Urol Rep. 2014;15:392.

29. Gillies DJ, Gardi L, De Silva T, et al. Real-time registration of 3D to 2D ultrasound images for image-guided prostate biopsy. Med Phys. 2017;44:4718–4723.

30. Lemptang S, Stringer T, Lizdas D. Visualized prostate biopsy: an intuitive three-dimensional user interface for systematic and targeted biopsy. J Endourol. 2021;35:1198–1203.